ArticleCancer research2020
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.Signal transduction and targeted therapy · 2026Article
- Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling.Nature communications · 2025Article
- Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.Journal for immunotherapy of cancer · 2025Article
- Regulatory T cells in cancer: from immunosuppression to therapeutic targeting.Frontiers in immunology · 2025Review
- Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer.Frontiers in immunology · 2025Review
- Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.Molecular cancer · 2024Article
- Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8Signal transduction and targeted therapy · 2024Article
- Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.Immunity · 2024Review
- Network Cluster Analysis of PPI and Phenotype Ontology for Type 1 Diabetes Mellitus.Iranian journal of biotechnology · 2024Article
- Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.Cell reports. Medicine · 2023Article
- Expansion of circulating stem-like CD8Nature communications · 2023Article
- Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects.Journal for immunotherapy of cancer · 2023Article
- Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.Cancer research · 2022Article
- Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.Science advances · 2022Article
- Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.Aging and cancer · 2022Article
- Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.Frontiers in immunology · 2022Review
- Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.Frontiers in immunology · 2022Review
- The Prognostic Model and Drug Sensitivity ofFrontiers in molecular biosciences · 2022Article
- CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.Journal for immunotherapy of cancer · 2021Article
- CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.Oncoimmunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Justin M Drerup *Department of Cell Systems and Anatomy, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas.
Yilun Deng *Department of Medicine, University of Texas Health San Antonio, Texas.
Sri Lakshmi PandeswaraDepartment of Medicine, University of Texas Health San Antonio, Texas.
Álvaro S PadrónDepartment of Medicine, University of Texas Health San Antonio, Texas.
Ryan M ReyesDepartment of Microbiology, Immunology and Molecular Genetics, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas.ORCID 0000-0002-9562-5809
Xinyue ZhangSun Yat-sen University, Guangzhou, Guangdong, P.R.China.
Jenny MendezDepartment of Medicine, University of Texas Health San Antonio, Texas.
Aijie LiuDepartment of Medicine, University of Texas Health San Antonio, Texas.
Curtis A ClarkDepartment of Medicine, University of Texas Health San Antonio, Texas.
Wanjiao ChenXiangya Medical School, Changsha, Hunan, China.
José R Conejo-GarciaDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Vincent HurezDepartment of Medicine, University of Texas Health San Antonio, Texas.
Harshita GuptaDepartment of Medicine, University of Texas Health San Antonio, Texas.ORCID 0000-0003-1003-2658
Tyler J CurielDepartment of Medicine, University of Texas Health San Antonio, Texas. curielt@uthscsa.edu.ORCID 0000-0001-6962-9411
The University of Texas Health Science Center at San Antonio · USChangsha Medical University · CNMoffitt Cancer Center · USSun Yat-sen University · CN
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MInstitute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3MInstitute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR002645 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2018 to 2022
$20.4MInstitute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR001120 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2013 to 2017
$16.5MTRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4MVascular Leukocytes Influence the Tumor MicroenvironmentR01CA124515 · NCI · WISTAR INSTITUTE · PI Jose R Conejo-Garcia · 2007 to 2026
$7.1MInitiation and Evolution of the Ovarian Cancer MicroenvironmentR01CA157664 · NCI · WISTAR INSTITUTE · PI CONEJO-GARCIA, JOSE R · 2011 to 2020
$3.8M(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltrationR01CA205965 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI REEVES, WILLIAM BRIAN · 2017 to 2021
$3.2M(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapyR01CA231325 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CURIEL, TYLER J., SHEN-ORR, SHAI SHLOMO · 2018 to 2022
$3.1MNRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8MB7-H1 Signaling in Ovarian CancerR01CA164122 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CURIEL, TYLER J. · 2012 to 2016
$1.5MSouth Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1MNCATS NIH HHS TL1 TR001119NCATS NIH HHS TL1 TR002647NCATS NIH HHS UL1 TR001120NCATS NIH HHS UL1 TR002645NCATS NIH HHS UM1 TR004538NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA124515NCI NIH HHS R01 CA157664NCI NIH HHS R01 CA164122NCI NIH HHS R01 CA205965NCI NIH HHS R01 CA231325NIA NIH HHS T32 AG021890NIGMS NIH HHS T32 GM113896
Abstract
The IL2 receptor (IL2R) is an attractive cancer immunotherapy target that controls immunosuppressive T regulatory cells (Treg) and antitumor T cells. Here we used IL2Rβ-selective IL2/anti-IL2 complexes (IL2c) to stimulate effector T cells preferentially in the orthotopic mouse ID8agg ovarian cancer model. Despite strong tumor rejection, IL2c unexpectedly lowered the tumor microenvironmental CD8
Indexed as
AnimalsAscitesB7-H1 AntigenCD8-Positive T-LymphocytesFemaleImmune ToleranceImmunity, CellularImmunologic MemoryImmunotherapyInterleukin-2Interleukin-2 Receptor beta SubunitMelanoma, ExperimentalMiceMice, Inbred C57BLOvarian NeoplasmsPhenotypeB7-H1 AntigenIL2RB protein, humanInterleukin-2Interleukin-2 Receptor beta SubunitReceptors, Interleukin-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.